Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com

RnRMarketResearch.com adds "Polycystic Ovarian Syndrome – Pipeline Review, H1 2015" report to its store. The report provides an overview of the polycystic ovarian syndrome's therapeutic pipeline.

Dallas, TX (PRWEB) February 27, 2015

The report "Polycystic Ovarian Syndrome – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for polycystic ovarian syndrome. Polycystic ovary syndrome is a problem in which a woman's hormones are out of balance. Polycystic ovary syndrome is a common problem among teenage girls and young women. The cause of polycystic ovary syndrome is unknown. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. The complete report is available @ http://www.rnrmarketresearch.com/polycystic-ovarian-syndrome-pipeline-review-h1-2015-market-report.html.

The symptoms of polycystic ovary syndrome can vary from woman to woman. Some of the symptoms of polycystic ovary syndrome include infertility, hirsutism, metabolic syndrome, diabetes, obstructive sleep apnea, acne, oily skin, dandruff, pelvic pain and depression. The report also reviews key players involved in the therapeutic development for polycystic ovarian syndrome and special features on late-stage and discontinued projects. Companies discussed in this "Polycystic Ovarian Syndrome – Pipeline Review, H1 2015" report include AstraZeneca PLC, Crinetics Pharmaceuticals, Inc., EffRx Pharmaceuticals S.A., Euroscreen S.A., Merck KGaA, and Neurocrine Biosciences, Inc.

Drugs profile discussed in this report include AZD-4901, Choriogonadotropin alfa, ESN-364, Metformin hydrochloride, Small Molecule to Antagonize GnRH for Endometriosis, Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome, Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia, Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome, and Synthetic Peptide to Antagonize GPR54 for Women's Health, Male Health and Oncology. Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269608. (This is a premium report priced at US$2,000 for a single user Llicense.)

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Featured news and press releases covered by this report include: Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364; Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome; Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations.

Table of contents

List of Tables
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2015
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Polycystic Ovarian Syndrome - Pipeline by AstraZeneca PLC, H1 2015
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H1 2015
Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H1 2015
Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H1 2015
Polycystic Ovarian Syndrome - Pipeline by Neurocrine Biosciences, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Polycystic Ovarian Syndrome Therapeutics - Recent Pipeline Updates, H1 2015
Polycystic Ovarian Syndrome - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2015
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015

Explore more reports on the women's health therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics.

About Us:
ReportsnReports.com is a database of selected syndicated market reports for global and Chinese industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

For the original version on PRWeb visit: http://www.prweb.com/releases/2015-polycystic-ovarian/syndrome-pipeline-review/prweb12549210.htm